Representing the first study to employ Metabolic Activity Diffusion Imaging (MADI) within human brain cancer, this thesis serves as a demonstration of MADI's ability to probe cellular metabolism and cellular properties to evaluate tumor progression status in resected human gliomas. Three goals were pursued: (i) MADI's ability to differentiate normal tissue, tumor progression, and pseudoprogression, (ii) how MADI compares to a common metabolic activity imager FDG-PET, and (iii) identification of limitations and weaknesses in the current MADI approach.